UGT1A7

UDP-glucuronosyltransferase 1A7 · Q9HAW7 · UGT1A7 on Sugi Atlas →

3,069 patent compounds predicted against UGT1A7, 2,495 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Diclofenac (SCHEMBL2799)	1.00	1/20
Probenecid (SCHEMBL3663)	1.00	1/20
Diclofenac (SCHEMBL996716)	1.00	1/20
Probenecid (SCHEMBL1034640)	1.00	1/20
Diclofenac (SCHEMBL24010)	0.97	1/20
Diclofenac (SCHEMBL40785)	0.97	1/20
Diclofenac (SCHEMBL418230)	0.97	1/20
Diclofenac (SCHEMBL1178502)	0.97	1/20
Diclofenac (SCHEMBL1231246)	0.97	1/20
Diclofenac (SCHEMBL1651599)	0.97	1/20
Diclofenac (SCHEMBL2216520)	0.97	1/20
Diclofenac (SCHEMBL3176618)	0.97	1/20
Diclofenac (SCHEMBL3184302)	0.97	1/20
Diclofenac (SCHEMBL3466580)	0.97	1/20
Diclofenac (SCHEMBL4614418)	0.97	1/20
Diclofenac (SCHEMBL4615491)	0.97	1/20
Diclofenac (SCHEMBL6509236)	0.94	1/20
Diclofenac (SCHEMBL4566078)	0.89	1/20
Diclofenac (SCHEMBL2899504)	0.86	1/20
Diclofenac (SCHEMBL691812)	0.84	1/20

Clinical trials — most relevant to UGT1A7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians	PHASE4	UNKNOWN
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial	PHASE3	UNKNOWN
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer	PHASE3	COMPLETED
CBD for Pain Following Orthopedic Shoulder Surgery	PHASE1/PHASE2	RECRUITING
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
Paclitaxel and Irinotecan in Advanced Gastric Cancer	PHASE1/PHASE2	COMPLETED
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer	PHASE2	COMPLETED
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	PHASE2	ACTIVE_NOT_RECRUITING
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	PHASE2	COMPLETED
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours	PHASE1	UNKNOWN
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors	PHASE1	UNKNOWN
OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin	PHASE1	COMPLETED
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Study of NK012 in Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene	PHASE1	COMPLETED
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors	PHASE1	COMPLETED
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors	PHASE1	COMPLETED
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors	PHASE1	COMPLETED
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes	PHASE1	RECRUITING
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype	nan	UNKNOWN
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C	nan	COMPLETED
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI	nan	COMPLETED
Escalated Dose of Irinotecan in mCRC	nan	COMPLETED
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a UGT1A7 binder may also engage these)

Protein	Name	Similarity
UGT1A9	UDP-glucuronosyltransferase 1A9	1.000	landscape →
UGT1A8	UDP-glucuronosyltransferase 1A8	1.000	landscape →
UGT1A10	UDP-glucuronosyltransferase 1A10	0.999	landscape →
Q64633	—	0.990	Q64633 →
Q62452	—	0.986	Q62452 →
Q6ZQM8	—	0.982	Q6ZQM8 →
Q64634	—	0.976	Q64634 →
UGT1A1	UDP-glucuronosyltransferase 1A1	0.948	landscape →
UGT1A3	UDP-glucuronosyltransferase 1A3	0.945	landscape →
UGT1A4	UDP-glucuronosyltransferase 1A4	0.941	landscape →
P35504	—	0.939	P35504 →
Q64550	—	0.937	Q64550 →
UGT1A6	UDP-glucuronosyltransferase 1A6	0.935	landscape →
Q63886	—	0.932	Q63886 →
Q64638	—	0.929	Q64638 →
P20720	—	0.926	P20720 →
Q28612	—	0.925	Q28612 →
Q5ZIN0	—	0.924	Q5ZIN0 →
Q4R766	—	0.923	Q4R766 →
Q64435	—	0.923	Q64435 →
Q64637	—	0.923	Q64637 →
Q9H3R1	—	0.922	Q9H3R1 →
B4F753	—	0.922	B4F753 →
B2GV54	—	0.922	B2GV54 →
Q99LR1	—	0.922	Q99LR1 →
Q6AYT7	—	0.921	Q6AYT7 →
O95803	—	0.921	O95803 →
P08430	—	0.920	P08430 →
Q9EQW8	—	0.919	Q9EQW8 →
Q9EQH7	—	0.919	Q9EQH7 →